{"name":"ATGC Co., Ltd.","slug":"atgc-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATGC-110","genericName":"ATGC-110","slug":"atgc-110","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Xeomin®","genericName":"Xeomin®","slug":"xeomin","indication":"Cervical dystonia (spasmodic torticollis)","status":"marketed"}]}],"pipeline":[{"name":"ATGC-110","genericName":"ATGC-110","slug":"atgc-110","phase":"phase_3","mechanism":"ATGC-110 is a small molecule that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Xeomin®","genericName":"Xeomin®","slug":"xeomin","phase":"marketed","mechanism":"Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Cervical dystonia (spasmodic torticollis)","Blepharospasm","Hemifacial spasm","Glabellar lines (aesthetic indication)","Crow's feet (aesthetic indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9jUEFwU0ZCWlI1dkVCbDdFdVpvYjNXaDQwRVotbVRkYkk4aDNWcmVGSWd5YlBqS2cwSkllcWRYaVVCWXo0SGlLNTY5dnpfaklwbkpFOEN6MS1ZeVhCcUdoQXNmLUdQZzItYjA1YjJSVzBwT1FSd2dPLXdQQUJreDA?oc=5","date":"2025-09-10","type":"pipeline","source":"Fortune Business Insights","summary":"Aesthetic Neurotoxin Market Size, Share | Growth Report [2034] - Fortune Business Insights","headline":"Aesthetic Neurotoxin Market Size, Share | Growth Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNd3VocktRay1OYk9RZGZKVW5SZ3lfQl93OGQ0OE1mU0gycXdkdGliVnlCdEo5Y2FaRTBJdnhMZGZxSXFyUEpUZElhU2JDdWFkZlpYVnk4amJpVkc4d2h1NFktVHlwYmNqQ001TjVOeWVoc1gtZHJmcUVrZHFFbkktaGc1STlkR3VJMVIwaEprQy14TVhfejk2Y0h6NzR4elVfUDk4NlRIMXNuSHREYmYyekdoM1luYjlxZ2pqZA?oc=5","date":"2024-12-09","type":"pipeline","source":"BioSpace","summary":"Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - BioSpace","headline":"Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOb0dQOEZDY1FvUWpIM3NuUGU0R1JQRF9IVXBNbU50Vjk1bTMyUXJVOXZuRlV5OFNWQzEwLUpQcnpiSzJiRkdRaGZpV2ZuSjI2RVZ5ZElzMDZmNDk1RVFSNm4yQWlCU3pvWUFxRDRPdHdMNHlkdUdJZlRoT1VHd0MyZm1NUU1lUQ?oc=5","date":"2024-08-23","type":"regulatory","source":"Yahoo Finance","summary":"China Botulinum Toxin Type A Market Report 2024-2030: Upper Face, Mid Face, Lower Face, Body, Female, Male Size, Share & Trends Analysis - Yahoo Finance","headline":"China Botulinum Toxin Type A Market Report 2024-2030: Upper Face, Mid Face, Lower Face, Body, Female, Male Size, Share &","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQSkFqNGdFZjd5VVI1WFB5U0RnSzFwaWQ5MUo2ZzRlbGRSQ0FIb01rUnBBa1lCUEluaEpPZTlMUERRcVA2V0p5Z295bzkyR2tiOFBCNGxGcVNYYWVuNERkYndVYWFkbllNMkNITFM0Q09UYmc5RDNLdkN3Vkg5dWtvN2wxekp1TEJ4RVhiQ0JmM0JHczFNcDE0Z3VR?oc=5","date":"2024-07-19","type":"pipeline","source":"grandviewresearch.com","summary":"China Botulinum Toxin Type A Market Size | Report, 2030 - grandviewresearch.com","headline":"China Botulinum Toxin Type A Market Size | Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1SV1JLcEI1TjlERlIzd3Z0emIwYzA3Q2Ftbzk0VWVsZWdYTTZnSU5Hd2VNYnlxV3hqdGcyeWNoYWpTSTcxVUlwRk5Nd3BUS0xZTmowOHFQRy1qZmJTTDdxSTdfNk10bnFodjc0SQ?oc=5","date":"2024-07-18","type":"pipeline","source":"Market.us Media","summary":"Top 10 Medical Aesthetics Companies | By Experienced Medical Practitioners - Market.us Media","headline":"Top 10 Medical Aesthetics Companies | By Experienced Medical Practitioners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBfUDh1NzBlYk9kT1RCZE9nNW55a2I5eWxicXNhbGdLbGFfWmVEbzBLNXdNN0VpTW0yZzdIaFVJbmxkcTlrSWcxd0kxM0VJRE1Nc0t2bEZodU5LZUtVV1BlU1d0ejBkZXhHdmRTTDhR0gFyQVVfeXFMTlRYMWxycmRZeTNKVjhHcEFta2NXd1BlaXJzdm9KRG5GMzEyUkhCX1BTVEl0WE13VVJGS2JrNThER0toekMtQ2tpa19ydlNCcE14YlduSmJkTlZKVmRwemRhcUVpSHZFMGJmN29UZkZHcnR3?oc=5","date":"2023-10-18","type":"deal","source":"koreabiomed.com","summary":"ATGC licenses out botulinum toxin to Sinclair - koreabiomed.com","headline":"ATGC licenses out botulinum toxin to Sinclair","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-04-02","type":"pipeline","source":"The Hans India","summary":"We developed novel mechanisms for crop protection: ATGC Biotech CMD - The Hans India","headline":"We developed novel mechanisms for crop protection: ATGC Biotech CMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBIV0ZSZkhvUHh1eEZxTm1pZm0tT2ktb25ia25aT191NTZSX1dmOWZqNWptdk1ZdmpsZ1dkRkxxbFNkSmNsUzBOTFJHQlk2ZGJoS2ZHRTlSSFB5MWNncmtvT0VMU19JR1M0cXp5SjhR0gFyQVVfeXFMTV85OXo3dTZvRTVVamNLRE1XalpCNHBybEJGa2xSaGYwVDJET1VCaDJDOVdCSk1TY0FwOUlCR3V0Z2xLRXVPNjgzd0hLQVhWRmRrd3oxWVJjaGpYd0hpUllIdXdOYk10ZjV5eC1VTmtyRTJB?oc=5","date":"2022-08-04","type":"deal","source":"koreabiomed.com","summary":"ATGC signs European license agreement with RELIFE for novel botulinum toxin type A - koreabiomed.com","headline":"ATGC signs European license agreement with RELIFE for novel botulinum toxin type A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQdFo5ZzE0WWdtXzNFY0RpSGdNWDk4cFd1TVNpSE84bjJRejd6a2x4c2xFVm9nZlE0RUhWQ0hISm1DeFBIZlZPYllOc3lQcWl3M3JncC1MSFdEU1VZcnBlR212STZRYlk1bVBQV192eGZCWjl2VUpDZmVqZXA0eGpYVHg3UmJkaURfTFBWMTRZS3dCTUh0bktMU09telZOd1JhdVN3ejR5azFydkphdV9SUFNMdEcyMzAybDEtd2NYYzN1V3BTQ2VYODFKaWp3Q29EOVQwdzJrY1lHeEtmdndoMNIB5gFBVV95cUxPUS1HYVZnV3hPbE90c2pySkxPTEVwU2FoWXJxc1MyUFdkaEkwVEtuWGF0NEJiLVUzNmJCRkRhU2lCQnV1QWllRkFobHlSUUxtUVd0N1FsM29vR00tWjNUYUVFbXM2V1NseVl3cHpicWhFSnhFek9yY1AwektjaWc4b1RyNFhzbjRzbGJVaWplZzFEQkZPazI5Wm53NUQ1SlFOV0JiMFgyRGhxY2I4bi1PSkZnazJ4a1lMbXo1cy13cGdpYjRNV3RDb2ZQQ1VfVnV1c0xJM3pSdHBweDVaVUxBSjUyeHVvdw?oc=5","date":"2021-03-15","type":"pipeline","source":"ET HealthWorld","summary":"Natco Pharma forays into pheromone-based technology for integrated pest management - ET HealthWorld","headline":"Natco Pharma forays into pheromone-based technology for integrated pest management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTjJRWXdMcm1rckk3enZWMUdlcGxPcmtNemNNNXZxY3lZUUVGc2ZHUDBlZU9NMnp5cVlVTFBSeXZ4aUVoZkFDbzU3bjBhSXNENmlTRk8xRlNrWGRjdTZDMUdrQ3l3cUc5UXFmU3lOTlQwaXZIb0xqMV9naTMxeDhKQ0pPenhPak9zTlY1czdMN0FwX05KdGJwZWFJR2dUU01XSzVN0gGoAUFVX3lxTE1sSnljZ3F3ODMzVUE0REU3dFFiMnNCbU02UTlSYmRKRy0tdTJIV19WSXBVeVRPbU9FSzNUQ2FBYld4N0hNMW5zYXlTaFNYVnpncFNPbmxoQWYyU1UtdmF4YTRYbHBZbi0tN21lRGswUGxPems5QnZlX0l0M05OS1NOVzlwRk1ZejZmdnI3ZnlrQWZOaEhyMmgyQkp0UEhtMmNLXzVteHJ1Mg?oc=5","date":"2021-03-15","type":"pipeline","source":"Express Pharma","summary":"NATCO ventures into Pheromone based tech for Integrated Pest Management - Express Pharma","headline":"NATCO ventures into Pheromone based tech for Integrated Pest Management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE4tLUh3Mm1sUjAtTlZ2RThON3pQanExeWZzNTFaTWE1eTN5Z2VXVEdKejB3YXhxTW8tazFscHVHeTg1M19fMV92R0s4Zzkyc2xBLTEwaUhKdWo0dlU?oc=5","date":"2019-10-21","type":"deal","source":"EurekAlert!","summary":"Merger to bring the next generation of insect control to the global marketplace - EurekAlert!","headline":"Merger to bring the next generation of insect control to the global marketplace - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQOEFubU53dTVkeWRhdTBGTHlBamFBMVNBaEh4emFDVHhBMnlZaFIwc1YzZUQ5MUlDLWhaRk5adW9jZlZPZWVVV053QmtyUm9BXzgtT0x6dGZGUHZHeFBVQkFXdTRHYlVWVkE5bXRIbDlESEdsVlprM0RGcnVBVjczTFlyVzFmLXJZcE9ScnNrb0J3UU0?oc=5","date":"2019-06-22","type":"pipeline","source":"Fortune Business Insights","summary":"Facial Injectables Market Size, Share And Global Report, 2034 - Fortune Business Insights","headline":"Facial Injectables Market Size, Share And Global Report, 2034","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}